• Sun. Jan 16th, 2022

Chronic lymphocytic leukemia, ibrutinib benefits alone and in mix

Byeditorial

May 31, 2021

New data demonstrate the benefits of ibrutinib in chronic lymphocytic leukemia (CLL) patients, both in combination and as monotherapy. Janssen, a pharmaceutical company of the American group Johnson & Johnson, will present the new results at the 2021 Congress of Asco, the American Society of Clinical Oncology. The Phase 2 Captivate study, in the cohort of patients with fixed duration treatment of ibrutinib plus venetoclax – summarizes the company in a note – shows that 95% of treated patients survive progression-free after 2 years, with significant remissions in all subgroups, including patients with high-risk LLC. Furthermore, the long-term results of the Resonate-2 study, which to date represents the longest phase 3 follow-up, of 7 years, for Bruton tyrosine kinase (Btk) inhibitors, indicate a strengthening of the benefits in terms of long-term survival and an established safety profile of ibrutinib monotherapy for patients with CLL, a type of non-Hodgkin’s lymphoma and the most common form of leukemia in adults. “The positive results of the Captivate study – says Craig Tendler, Vice President, Clinical Development and Global Medical Affairs, Oncology, Janssen Research & Development – demonstrate the potential of ibrutinib plus venetoclax therapy, thanks to a complementary mechanism of action, to induce deep responses in combination with a fixed duration once a day, regimen that can be administered on an outpatient basis for younger, healthy patients. ” While “the results of Resonate-2 – he adds – further support the long-term benefit of monotherapy with ibrutinib in the first line in patients with CLL. The breadth and importance of the growing number of data continues to indicate this treatment as a standard of treatment and to enhance its impact on progression-free and overall survival “.” Continuous treatment with ibrutinib in patients with CLL is now an established standard of care, also used in those at high risk – comments Paolo Ghia, professor of medical oncology at the Vita-Salute San Raffaele University in Milan and principal investigator of the Captivate study – The latest data from the study emphasize that ibrutinib, administered orally in combination with venetoclax, also determines a high 2-year progression-free survival rate, allowing to patients remission without treatment “.” Ibrutinib – remembers Edmond Chan, Emea Therapeutic Area Lead Haematology , Janssen-Cilag Ltd – was the first Btk inhibitor approved in Europe and has been used in the treatment of over 230,000 patients worldwide. It is also the first Btk inhibitor studied in a fixed-duration combined regimen treatment. The latest data to be presented at Asco reinforce the potential of ibrutinib as a key treatment option across the entire LLC landscape and add further evidence on its efficacy and safety profile. “

One thought on “Chronic lymphocytic leukemia, ibrutinib benefits alone and in mix”
  1. editorial says:

    https://zenodo.org/record/4848287
    https://zenodo.org/record/4848319
    https://zenodo.org/record/4848281
    https://zenodo.org/record/4848313
    https://zenodo.org/record/4848291
    https://zenodo.org/record/4848277
    https://zenodo.org/record/4848299
    https://zenodo.org/record/4848259
    https://zenodo.org/record/4848265
    https://zenodo.org/record/4848293
    https://zenodo.org/record/4848297
    https://zenodo.org/record/4848249
    https://zenodo.org/record/4848311
    https://zenodo.org/record/4848283
    https://zenodo.org/record/4848309
    https://zenodo.org/record/4848307
    https://zenodo.org/record/4848225
    https://zenodo.org/record/4848271
    https://zenodo.org/record/4848241
    https://zenodo.org/record/4848305
    https://zenodo.org/record/4848417
    https://zenodo.org/record/4848347
    https://zenodo.org/record/4848381
    https://zenodo.org/record/4848369
    https://zenodo.org/record/4848363
    https://zenodo.org/record/4848335
    https://zenodo.org/record/4848345
    https://zenodo.org/record/4848411
    https://zenodo.org/record/4848355
    https://zenodo.org/record/4848413
    https://zenodo.org/record/4848415
    https://zenodo.org/record/4848373
    https://zenodo.org/record/4848391
    https://zenodo.org/record/4848383
    https://zenodo.org/record/4848401
    https://zenodo.org/record/4848349
    https://zenodo.org/record/4848393
    https://zenodo.org/record/4848359
    https://zenodo.org/record/4848339
    https://zenodo.org/record/4848325
    https://zenodo.org/record/4848327
    https://zenodo.org/record/4848375
    https://zenodo.org/record/4848405
    https://zenodo.org/record/4848387
    https://zenodo.org/record/4848371
    https://zenodo.org/record/4848337
    https://zenodo.org/record/4848365
    https://zenodo.org/record/4848395
    https://zenodo.org/record/4848361
    https://zenodo.org/record/4848377

Comments are closed.